Attitudes Of Chinese Cancer Patients Toward The Clinical Use Of Artificial Intelligence
Attitudes Of Chinese Cancer Patients Toward The Clinical Use Of Artificial Intelligence
复制标题
DOI：
10.2147/ppa.s225952
复制
发表时间：
2019-01-01
影响因子：
2.2
通讯作者：
Jiang, Yu
中科院分区：
文献类型：
--
作者：
Yang, Keyi;Zeng, Zhi;Jiang, Yu
目的：人工智能(AI)在包括医学领域在内的许多领域发挥着重要作用。然而，我们仍然缺乏证据来支持癌症患者是否会接受人工智能的临床应用。本研究旨在了解中国癌症患者对人工智能医学临床应用的态度，并分析其可能的影响因素。结果：有效应答率为76.3%(402/527)。大多数癌症患者在诊断和治疗的两个阶段都信任AIMS，而听说过AIMS的参与者更有可能在诊断阶段信任他们。当AIM的诊断偏离人类医生的S时，少数民族和从未接受过化疗的中医患者更倾向于选择AIM，当AIM的治疗建议与人类医生的建议不一致时，男性参与者和接受过中医或手术的患者更倾向于选择AIM。结论：大多数中国癌症患者在一定程度上相信AIM。然而，大多数人仍然认为，当肿瘤医生的意见出现分歧时，他们更值得信任。参与者的性别、种族、接受的治疗以及与AIM相关的知识可能会影响他们对AIM的态度。大多数参与者认为AIM将在未来帮助肿瘤医生，而很少有人真正相信肿瘤医生会完全被取代。
Purpose: Artificial intelligence (AI) plays a substantial role in many domains, including medical fields. However, we still lack evidence to support whether or not cancer patients will accept the clinical use of AI. This research aims to assess the attitudes of Chinese cancer patients toward the clinical use of artificial intelligence in medicine (AIM), and to analyze the possible influencing factors.Patients and methods: A questionnaire was delivered to 527 participants. Targeted people were Chinese cancer patients who were informed of their cancer diagnosis.Results: The effective response rate was 76.3% (402/527). Most cancer patients trusted AIMs in both stages of diagnosis and treatment, and participants who had heard of AIMs were more likely to trust them in the diagnosis phase. When an AIM's diagnosis diverged from a human doctor' s, ethnic minorities, and those who had received traditional Chinese medicine (TCM), had never received chemotherapy, were more likely to choose "AIM", and when an AIM's therapeutic advice diverged from a human doctor's, male participants, and those who had received TCM or surgery, were more likely to choose "AIM".Conclusion: Most Chinese cancer patients believed in the AIM to some extent. Nevertheless, most still thought that oncology physicians were more trustworthy when their opinions diverged. Participants' gender, race, treatment received, and AIM related knowledge might influence their attitudes toward the AIM. Most participants thought AIM would assist oncology physicians in the future, while little really believed that oncology physicians would completely be replaced.